Article
Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
19 Jun 2020
Abstract excerpt
Chimeric antigen receptor modified T cells (CAR-T) have yielded impressive clinical outcomes in treating hematopoietic malignancies. However, relapse has occurred in a substantial number of patients and limited the development of CAR-T therapy. Most underlying reasons can be attributed to poor persistence and rapid exhaustion of CAR-T cell in vivo. Despite multiple strategies developed, how to improve CAR-T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
